The Rare2030 Foresight Study – building a better future for people living with a rare disease

Eurordis, Rare Diseases Europe
The Voice of Rare Disease Patients in Europe

The Rare2030 Foresight Study – building a better future for people living with a rare disease

Rare2030 event discussion

The Rare2030 Foresight Study continues! After one year of reflection and with a nearly 200-person-strong Panel of Experts, the study has reached its third phase.

Led by EURORDIS with nine project partners and initiated with the support of the European Commission and European Parliament, the Rare2030 Foresight Study is laying the foundations for policies that will create a better future for people living with a rare disease in Europe. Watch the new Rare2030 scenarios video.

RareConnectRARECONNECT

Share your story & connect with others worldwide in the multilingual FOXP1 community

0487fbe8-01d4-4df5-a7ed-0d425f189b55.gif
EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTSEUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS

1,500 people attended the first-ever exclusively online ECRD last week!

0487fbe8-01d4-4df5-a7ed-0d425f189b55.gif
EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTSEURORDIS BLACK PEARL AWARDS

Nominations for the EURORDIS Black Pearl Awards 2021 are now open

0487fbe8-01d4-4df5-a7ed-0d425f189b55.gif
EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTSRARE BAROMETER VOICES

See preliminary results from the EURORDIS survey on how COVID-19 affects people living with a rare disease 

0487fbe8-01d4-4df5-a7ed-0d425f189b55.gif
WHAT'S NEW AT EURORDIS?WHAT'S NEW AT EURORDIS?

Out now: ten new Rare Impact country reports on how to improve patients' access to cell & gene therapies

0487fbe8-01d4-4df5-a7ed-0d425f189b55.gif
PATIENTS ADVANCING RESEARCH PATIENTS ADVANCING RESEARCH

EURORDIS contributes to new IRDiRC Orphan Drug Development Guidebook

0487fbe8-01d4-4df5-a7ed-0d425f189b55.gif
MEMBERS' CORNERORPHAN MEDICINES

1 new marketing authorisation

0487fbe8-01d4-4df5-a7ed-0d425f189b55.gif

Follow us

twitter.gif  EURORDIS facebook EURORDIS facebook

This publication (or activity) has been funded with support from the European Union's Health Programme. This material only reflects the views of the author, and funders cannot be held responsible for any use which may be made of the information contained herein.

afmtelethonHealth Programme of the European Union